This article has been cited by
1Macitentan in daily clinical practice: A single centre, 1-year experience
S. Cadenas-Menéndez,P. Álvarez-Vega,J. Martín-Moreiras,M. Barreiro-Pérez,M.Á. Gómez-Sánchez,P.L. Sánchez-Fernández
2Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan
Timothy Tynan,Kathryn Hird,Tara Hannon,Eli Gabbay
Journal of International Medical Research.2019;47(5)2177
3Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
M. C. J. van Thor,L. ten Klooster,R. J. Snijder,J. C. Kelder,J. J. Mager,M. C. Post
4A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension
Martin Bedan,Daniela Grimm,Markus Wehland,Ulf Simonsen,Manfred Infanger,Marcus Krüger
Basic & Clinical Pharmacology & Toxicology.2018;123(2)103
5New Tactics for the Treatment of Pulmonary Hypertension: Switching to a More Effective Therapy
N. A. Tsareva,S. N. Avdeev
6A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment
Robert S. Kerbel
The Cancer Journal.2015;21(4)274
7Association therapy with macitentan added to sildenafil in a thalassemic patient with pulmonary hypertension
Michele Correale,Stefano Zicchino,Ilenia Monaco,Natale Daniele Brunetti,Matteo Di Biase
International Journal of Cardiology.2016;220(4)80
8A Novel Synthesis of Macitentan, an Endothelin Receptor Antagonist
Majid Nami,Sara Nasiri Sovari,Yaghoub Haghighatnia,Minoo Dabiri,Peyman Salehi
Organic Preparations and Procedures International.2017;49(3)258
9A focus on riociguat in the treatment of pulmonary arterial hypertension
Anne Kathrine Toxvig,Markus Wehland,Daniela Grimm,Manfred Infanger,Marcus Krüger
Basic & Clinical Pharmacology & Toxicology.2019;125(3)202
10The use of Macitentan in Fontan circulation: a case report
Polyvios Demetriades,Amir Aziz,Robin Condliffe,Sarah E. Bowater,Paul F. Clift
BMC Cardiovascular Disorders.2017;17(1)202